Back to discover
Disease

Eosinophilic Esophagitis

Late-stage therapeutic developmentEmerging research
MeSHEosinophilic Esophagitis
1
Publications
18
Clinical trials
2025
Latest publication
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this disease.

Long-term Safety and Efficacy of Budesonide Oral Suspension for Eosinophilic Esophagitis: A 4-Year, Phase 3, Open-Label Study.

Research2025-02-13Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association

Accelerated approval: Jorveza (EMA)

Regulatory2018-01-08EMA

Approval: Dupixent (EMA)

Regulatory2017-09-26EMA

What's happening now

An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.

Executive briefingUpdating summary…Momentum: Moderate
Key developments
  • 2 clinical trials expected to report results, the earliest in Q4 2026.
Upcoming Milestones
Clinical Milestones7View
Results posted 3
Results expected 2
Recently completed 2
Activity timeline7

Therapeutic landscape

Therapies with a regulatory footing for this condition, alongside the wider set of agents co-studied with it in the literature.

Approved & established therapies
Budesonideapproved

Accelerated approval — Jorveza is indicated for the treatment of eosinophilic esophagitis (EoE) in adults (older… (2018)

Dupilumabapproved

Approval — Atopic dermatitis Adults and adolescents Dupixent is indicated for the treatment of mode… (2017)

Clinical trials

15 sponsors · 1 new · 1 completed in the last 12 months (net +1)

The current development programme across all trial phases.

Clinical programme
18
All trials
6
Active
15
Late-stage
6
Completed
Late-stage studies

A Randomized Study Evaluating 2 Dose Regimens of Dupilumab in Children ≥6 Months of Age Weighing ≥5 to <15 kg With Active Eosinophilic Esophagitis

Phase 3 · Recruiting · Regeneron Pharmaceuticals

Double-blind, Randomized, Non-inferiority Phase III Trial on the Efficacy and Tolerability of 2 mg Once Daily vs. 1 mg Twice Daily Budesonide Orodispersible Tablets in Adults With Eosinophilic Esophagitis

Phase 3 · Recruiting · Dr. Falk Pharma GmbH

A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Phase 3 Efficacy and Safety Study of Tezepelumab in Patients With Eosinophilic Esophagitis (CROSSING).

Phase 3 · Active, not recruiting · AstraZeneca

Dupilumab for Eosinophilic Esophagitis With Severe Strictures (DESTRICT Study)

Phase 4 · Active, not recruiting · University of North Carolina, Chapel Hill

Effect of Dupilumab on Esophageal Peristaltic Function in Participants with Eosinophilic Esophagitis

Phase 4 · Recruiting · University of California, San Diego

Proton Pump Inhibitor (PPI) Response in Eosinophilic Esophagitis Assessed by Transnasal Endoscopy (TNE)

Phase 4 · Active, not recruiting · University of Colorado, Denver
Recently completed

A Phase 3, Multicenter, Multinational, Open-Label Extension Study to Evaluate the Long-Term Safety of CC-93538 in Adult and Adolescent Subjects With Eosinophilic Esophagitis

Phase 3 · Completed · Celgene

Efficacy of Dupilumab on Facilitated Food Introduction in Eosinophilic Esophagitis

Phase 4 · Completed · Children's Hospital of Philadelphia

Fluticasone Propionate Oral Disintegrating Tablet Formulation in Eosinophilic Esophagitis: A Randomized, Double-blind, Placebo-Controlled 24-Week Induction Study of APT-1011, Followed by a Single-arm Open-label Extension, in Adult Subjects With Eosinophilic Esophagitis

Phase 3 · Completed · Ellodi Pharmaceuticals, LP

Effectiveness of Cycling of Topical Steroid Therapy in Maintaining Clinical and Histologic Remission in Eosinophilic Esophagitis

Phase 4 · Completed · University Hospitals Cleveland Medical Center

A Multi-center, Randomized, Double Blind, Parallel-arm, Placebo Controlled Trial of Mepolizumab for Treatment of Adults and Adolescents With Active Eosinophilic Esophagitis and Dysphagia-predominant Symptoms

Phase 2 · Completed · University of North Carolina, Chapel Hill

A Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Dupilumab in Pediatric Patients With Active Eosinophilic Esophagitis

Phase 3 · Completed · Regeneron Pharmaceuticals

Regulatory timeline

Drug regulatory events matched to this condition by indication — EMA.

First approvals
2018emaAccelerated approval — Budesonide· Jorveza is indicated for the treatment of eosinophilic esophagitis (EoE) in adults (older than 18 years of age). Jorveza 0.2&nbsp;mg/mL oral suspension is indicated for the treatment of&nbsp;eosinophilic esophagitis (EoE)&nbsp;in paediatric patients 2&nbsp;to 17&nbsp;years of age. source ↗
2017emaApproval — Dupilumab· Atopic dermatitis Adults and adolescents Dupixent is indicated for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy. Children 6 months to 11 years of age Dupixent is indicated for the treatment of severe atopic dermatitis in children 6 months to 11 years old who are candidates for systemic therapy. Asthma Adults and adolescents Dupixent is indicated in adults and adolescents 12 years and older as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (FeNO), see section 5.1, who are inadequately controlled with high dose inhaled corticosteroids (ICS) plus another medicinal product for maintenance treatment. Children 6 to 11 years of age Dupixent is indicated in children 6 to 11 years old as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (FeNO), who are inadequately controlled with medium to high dose inhaled corticosteroids (ICS) plus another medicinal product for maintenance treatment. Chronic rhinosinusitis with nasal polyposis (CRSwNP) Dupixent is indicated as an add-on therapy with intranasal corticosteroids for the treatment of adults with severe CRSwNP for whom therapy with systemic corticosteroids and/or surgery do not provide adequate disease control. Prurigo Nodularis (PN) Dupixent is indicated for the treatment of adults with moderate-to-severe prurigo nodularis (PN) who are candidates for systemic therapy. Eosinophilic esophagitis (EoE) Dupixent is indicated for the treatment of eosinophilic esophagitis in adults, adolescents and children aged 1 year and older, weighing at least 15 kg, who are inadequately controlled by, are intolerant to, or who are not candidates for conventional medicinal therapy. Chronic obstructive pulmonary disease (COPD) Dupixent is indicated in adults as add-on maintenance treatment for uncontrolled chronic obstructive pulmonary disease (COPD) characterised by raised blood eosinophils on a combination of an inhaled corticosteroid (ICS), a long-acting beta2-agonist (LABA), and a long-acting muscarinic antagonist (LAMA), or on a combination of a LABA and a LAMA if ICS is not appropriate. Chronic Spontaneous Urticaria (CSU) Dupixent is indicated for the treatment of moderate to severe chronic spontaneous urticaria in adults, adolescents and children (2 years and above) patients with inadequate response to H1 antihistamines and who are naive to anti-IgE therapy for CSU. source ↗

European Medicines Agency (CC BY 4.0). Events are matched to this condition by drug indication text — approvals/updates for drugs indicated for it, not disease-specific acts.

Research activity

1 papers

Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.

Most influential

Long-term Safety and Efficacy of Budesonide Oral Suspension for Eosinophilic Esophagitis: A 4-Year, Phase 3, Open-Label Study.

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2025 · 4 cites
Recent publications

Long-term Safety and Efficacy of Budesonide Oral Suspension for Eosinophilic Esophagitis: A 4-Year, Phase 3, Open-Label Study.

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2025 · 4 cites
Major themes3
  • Anti-Inflammatory Agents1
  • Budesonide1
  • Eosinophilic Esophagitis1
Leading journals1
  • Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association1
Leading researchers8
  • Boules M1
  • Collins MH1
  • Dellon ES1
  • Falk GW1
  • Goodwin B1
  • Hirano I1
  • Katzka DA1
  • Mukkada VA1
Affiliations (unnormalised)6
  • Center for Esophageal Diseases and Swallowing1
  • Cincinnati Children's Hospital Medical Center1
  • Division of Pathology and Laboratory Medicine1
  • Kenneth C. Griffin Esophageal Center1
  • NewYork-Presbyterian/Columbia University Irving Medical Center1
  • Takeda Development Center Americas1

Reference

Authoritative identity, definition & identifiers.

Defined in MeSH

Chronic ESOPHAGITIS characterized by esophageal mucosal EOSINOPHILIA. It is diagnosed when an increase in EOSINOPHILS are present over the entire esophagus. The reflux symptoms fail to respond to PROTON PUMP INHIBITORS treatment, unlike in GASTROESOPHAGEAL REFLUX DISEASE. The symptoms are associated with IgE-mediated hypersensitivity to food or inhalant allergens.

Identifiers
MeSHEosinophilic Esophagitis
References & data sources
  • Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
  • Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
  • Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
  • Related entities are derived from literature co-mention (studied together) — associative, not causal.